Dimerization and activation of the common transducing chain (gp130) of the cytokines of the IL-6 family by mAb.

@article{Autissier1998DimerizationAA,
  title={Dimerization and activation of the common transducing chain (gp130) of the cytokines of the IL-6 family by mAb.},
  author={Patrick A Autissier and John de Vos and Janny Liautard and N. N. Tupitsyn and Christelle Jacquet and N Chavdia and Bernard Klein and Jean Brochier and Jean Philippe Gaillard},
  journal={International immunology},
  year={1998},
  volume={10 12},
  pages={
          1881-9
        }
}
The objective of our research was to study the mechanisms of activation of mAb against the gp130 transducer chain common to the IL-6 cytokine family. It has been found that among the 56 anti-gp130 available worldwide, none was able to activate the growth of IL-6-dependent myeloma cell lines. When certain of them were associated in pairs they allowed the cells to grow; alone, they were inhibitory. The same activation was also obtained by cross-linking certain anti-gp130 mAb on the cell membrane… 
View on PubMed
academic.oup.com
24 Citations
Background Citations
8
Methods Citations
1

24 Citations

Citation Type

Citation Type

Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors
TLDR
It is found that these monoclonal antibodies against the human gp130 interleukin-6 transducer supported the long-term survival of primary myeloma cells from five patients with primary plasma cell leukemia but failed to induce their long- term growth.
Identification of Agonistic and Antagonistic Antibodies against gp190, the Leukemia Inhibitory Factor Receptor, Reveals Distinct Roles for Its Two Cytokine-binding Domains*
TLDR
Results demonstrate that the two CRH domains of gp190 play different functions in ligand binding and receptor activation.
Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth
TLDR
The growth of INA-6 plasmacytomas in vivo under interleukin-6 withdrawal remains strictly dependent on glycop protein 130, and other glycoprotein 130 cytokines may substitute for interleucin- 6.
Orientational Constraints of the gp130 Intracellular Juxtamembrane Domain for Signaling*
TLDR
The results suggest that gp130-mediated activation of STATs is sensitive to rotational changes around the receptor axis perpendicular to the membrane, and suggests a new model concerning the gp130 activation mode in which the relative orientation of the cytoplasmic regions seems to be critical for further signal transduction.
The role of IL-6 and STAT3 in inflammation and cancer.
Structural Bases of Receptor-JAK-STAT Interactions
TLDR
This chapter reviews the structural bases of receptor-JAK-STAT interactions taking the interleukin (IL)-6 type cytokine system as a paradigm.
Determinants governing the potency of STAT3 activation via the individual STAT3-recruiting motifs of gp130.
Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway.
TLDR
Using interleukin (IL)-6-dependent myeloma cell lines, IGF-I is shown to be as potent a survival and proliferation factor as IL-6 and to activate distinct downstream signalling molecules, suggesting a role for this cytokine in the pathophysiology of multipleMyeloma.
Jaks and cytokine receptors--an intimate relationship.
Functional properties of extracellular domains of transducer receptor gp130
TLDR
The functional significance of certain parts of gp130 extracellular domains are examined, based on extensive accumulated data, andentials of a recently developed method for estimation of receptor activation at the level of epitope structure are discussed.
...
1
2
3
...

References

SHOWING 1-10 OF 19 REFERENCES
Activation of the gp130 signaling pathway by monoclonal antibodies directed against the gp130 molecule
TLDR
These panels of anti‐gp130 monoclonal antibodies are interesting tools to study the molecular interactions leading to gp130 activation and, from a practical point of view, valuable growth factors of hematopoietic stem cells.
gp130 Transducing Receptor Cross-linking Is Sufficient to Induce Interleukin-6 Type Responses (*)
TLDR
It is shown that gp130 cross-linking with the B-S12 monoclonal antibody was sufficient to generate functional IL-6 type responses in hematopoietic, neural, and hepatic cells.
Specific inhibition of IL-6 signalling with monoclonal antibodies against the gp130 receptor.
TLDR
Results show the presence of different gp130 epitopes specifically involved in the signaling induced by the cytokines of the gp130 family, which would be useful to better understand the mechanisms of the IL-6 signalling.
Epitope analysis of human IL-6 receptor gp80 molecule with monoclonal antibodies.
TLDR
Four different epitopes of the molecule were identified, either by cross-blocking experiments of mAb binding to IL6R in ELISA or by the biosensor Biacore technology, and these antibodies were able to inhibit the binding of IL-6 toIL-6R and the proliferation of the IL- 6-dependent XG-1 cell line.
Interleukin-6 family of cytokines and gp130.
TLDR
It is shown that IL-6, together with IL-3, induces the expansion of murine hematopoietic progenitor cells and to be responsible for stimulating resting cells to enter the Cl-phase, a fact that may explain the redundant activities of IL- 6 and LIF.
Interleukin‐6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti‐gp130 monoclonal antibodies
TLDR
The data show for the first time that mAb against gp130 can specifically block the action of distinct IL‐6‐type cytokines that signal through gp130, which might be of great value for therapeutic applications in diseases where a single cytokine action needs to be inhibited.
Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines.
TLDR
Results show for the first time that several Src kinases may become activated by IL-6 (p59Fyn, p56/59Hck, and p56Lyn) and associate with gp130 (p56/ 59Hck and p 56Lyn).
Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells.
TLDR
IL-6 super-antagonists are a useful tool for the study of myeloma in vitro and might constitute, in particular Sant7, effective IL-6 blocking agents in vivo.
Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders.
  • K. Yoshida, T. Taga, +15 authors T. Kishimoto
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 1996
TLDR
Results indicate that gp130 plays a crucial role in myocardial development and hematopoiesis during embryogenesis and some gp130-/- embryos show anemia due to impaired development of erythroid lineage cells.
Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors.
TLDR
The data indeed demonstrate that EPO and MoAb34 antagonize ligand-dependent cell proliferation with IC50 values of approximately 20 and 2 mumol/L, respectively, and the data for proliferation and differentiation activity were consistent with the receptor dimer formation on the cell surface predicted by the model.
...
1
2
...